Cardiovascular and musculskeletal co-morbidities in patients with alpha 1 antitrypsin deficiency.
about
Inflammatory cytokine response to exercise in alpha-1-antitrypsin deficient COPD patients 'on' or 'off' augmentation therapy.Biomarkers of systemic inflammation in farmers with musculoskeletal disorders; a plasma proteomic studyRosuvastatin Alters the Proteome of High Density Lipoproteins: Generation of alpha-1-antitrypsin Enriched Particles with Anti-inflammatory PropertiesCause-specific mortality in individuals with severe alpha 1-antitrypsin deficiency in comparison with the general population in Sweden.High density lipoproteins are modulators of protease activity: Implications in inflammation, complement activation, and atherothrombosis.Acute phase proteins as prospective risk markers for arterial stiffness: The Malmö Diet and Cancer cohort.Trophic Activity and Phenotype of Adipose Tissue-Derived Mesenchymal Stem Cells as a Background of Their Regenerative Potential.Cardiovascular risk in patients with alpha-1-antitrypsin deficiency.α1-Antitrypsin in fibromyalgia: results of a randomized, placebo-controlled, double-blind and crossover pilot trial.Free circulating active elastase contributes to chronic inflammation in patients on hemodialysis.Systemic comorbidities in bronchiectasis.Vascular inflammation and aortic stiffness: potential mechanisms of increased vascular risk in chronic obstructive pulmonary disease.Nutritional status and muscle dysfunction in chronic respiratory diseases: stable phase versus acute exacerbations.Lung Function and Aortic Calcification–Hardening the Evidence or Inflaming the Need for Further Research?Discovery of restless legs syndrome plasmatic biomarkers by proteomic analysis
P2860
Q33880491-7D519184-0A0A-45BA-9200-658D781B326BQ36012683-397377E2-7670-4B77-A826-F642ACB7B824Q36604395-A37E8E9C-034B-46CB-AF66-92D514194F83Q37142611-B923F4D8-B217-4B7F-9D1C-98924ADFDBD4Q38436472-66910CAA-7D81-45B9-993E-509417B7211BQ38651581-65CAF205-81F1-4466-89C5-F2CDA2976B99Q41056755-9E5A29C3-DC2A-4C83-8587-BD770B1B3FA0Q41717223-1856DB55-28B4-4B28-A317-446F37BACC78Q48778639-4ADF68EF-B638-4438-977A-70B923A20A96Q50091246-5888AC42-8E01-4972-ADA3-92F381BD18AEQ51349438-9E6CDA6B-53BD-4463-984A-736FDBD92FF2Q55112444-01202456-BA43-4984-8085-EBF0C3230D84Q55212210-B461C5D2-7A38-410C-8CA8-2D3B1E9ABAA0Q58057582-57AB5564-02C7-4571-8BB5-F0506A942538Q58702164-3E1A092D-5DF4-4470-ADE2-10878C11D50C
P2860
Cardiovascular and musculskeletal co-morbidities in patients with alpha 1 antitrypsin deficiency.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Cardiovascular and musculskele ...... lpha 1 antitrypsin deficiency.
@ast
Cardiovascular and musculskele ...... lpha 1 antitrypsin deficiency.
@en
Cardiovascular and musculskele ...... lpha 1 antitrypsin deficiency.
@nl
type
label
Cardiovascular and musculskele ...... lpha 1 antitrypsin deficiency.
@ast
Cardiovascular and musculskele ...... lpha 1 antitrypsin deficiency.
@en
Cardiovascular and musculskele ...... lpha 1 antitrypsin deficiency.
@nl
prefLabel
Cardiovascular and musculskele ...... lpha 1 antitrypsin deficiency.
@ast
Cardiovascular and musculskele ...... lpha 1 antitrypsin deficiency.
@en
Cardiovascular and musculskele ...... lpha 1 antitrypsin deficiency.
@nl
P2093
P2860
P356
P1433
P1476
Cardiovascular and musculskele ...... alpha 1 antitrypsin deficiency
@en
P2093
Bronwen A J Evans
Dennis J Shale
James M Duckers
John R Cockcroft
Nichola S Gale
Robert A Stockley
P2860
P2888
P356
10.1186/1465-9921-11-173
P577
2010-12-07T00:00:00Z
P5875
P6179
1031685724